Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

BioCT Careers page matches employers and job seekers

Have you visited the BioCT Careers page recently? This enhanced, interactive site matches job seekers and employers in the bioscience industry throughout Connecticut. Job seekers...

| By Bill Kelly

Connecticut Innovations to invest in Invixium 

Connecticut Innovations reports that it has closed on the initial $665,000 tranche of a $1 million investment in Invixium Access, a manufacturer of modern biometric solutions. Invixium was a winner...

| By Kelley Gipson

SpringWorks announces Phase 3 trial re desmoid tumors

SpringWorks Therapeutics reports that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase...

| By Kelley Gipson

Azitra expands technical team in Farmington

Azitra has announced the appointment of two distinguished scientists to expand the technical team and lead the expansion of its development programs. Travis Whitfill, co-founder, will...

| By Kelley Gipson

Bioarray to present at Cancer Cluster Showcase

Bioarray Genetics has been selected to present at the 2019 International Cancer Cluster Showcase as part of its North American and European cutting-edge oncology innovations group....

| By Kelley Gipson

Achillion reports positive interim data re ACH-4471

Achillion Pharmaceuticals has reported positive interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small...

| By Kelley Gipson

NextCure reports IPO pricing

NextCure announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share....

| By Kelley Gipson

Trevi Therapeutics raises $55M in IPO

Trevi Therapeutics has gone public, selling 5.5 million shares at $10 a share and raising $55 million. The company, which is developing a drug for...